Retro Biosciences
30-Second Executive Brief
Executive Assessment
Retro Biosciences functions as a regional institution within Healthcare & Life Sciences, backed by 47% sourcing coverage, though its relative influence is cooling.
- Maintains 3 mapped relationships across the graph
- 47% sourcing coverage across sourced relationships
- Tracked as regional institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Regional Institution
- Sourcing Coverage
- 47%
- Ecosystem Influence
- Moderate
- Strategic Momentum
- Decelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 3
- Technology Domains
- 3
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
Retro Biosciences is a longevity biotech startup backed by OpenAI CEO Sam Altman (a $180 million seed investment) developing therapies aimed at extending human healthspan, including a clinical-stage pill designed to enhance the body's ability to clear protein aggregates in Alzheimer's disease patients. The company reached a $1.8 billion valuation as of May 2026 after raising additional capital beyond its initial $1 billion Series A target of a $5 billion valuation, following a Q1 2025 $1 billion round that was, at the time, the largest single longevity-biotech funding deal on record.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source
- STAT News — Retro Biosciences reaches $1.8B valuationnews
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Retro Biosciences — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
Retro's $1.8B valuation is running well ahead of clinical validation, typical of the current longevity-biotech funding environment
32% confidenceRetro Biosciences reached a $1.8 billion valuation in May 2026 while still in its first clinical trial for its lead Alzheimer's protein-aggregate clearance therapy, backed heavily by a single prominent investor (Sam Altman).
This is InsightNodes' own interpretive read: a $1.8 billion valuation for a company with no completed clinical trials reflects investor conviction in the longevity-biotech thesis and founder/backer credibility more than de-risked clinical data -- this pattern (large valuations preceding clinical proof points) is common across the current wave of tech-billionaire-backed longevity biotechs (also visible at Altos Labs), and means Retro's near-term Alzheimer's trial results carry outsized importance for justifying the valuation relative to peers with more traditional, staged funding.
InsightNodes analysis of Retro Biosciences valuation · Aug 14, 2026
Retro Biosciences's Timeline
A sourced, dated history of Retro Biosciences's key moments — founding to present.
Jan 2021 · Founded with $180M Sam Altman seed investment
Retro Biosciences was founded with a $180 million seed investment from OpenAI CEO Sam Altman to develop therapies extending human healthspan.
2025-Q1 · Raises $1B, largest longevity-biotech deal on record
Retro Biosciences raised $1 billion in the largest single longevity-biotech funding deal on record at the time, initially targeting a $5 billion valuation.
May 2026 · Reaches $1.8B valuation, advances Alzheimer's clinical trial
Retro Biosciences reached a $1.8 billion valuation as of May 2026 while running its first clinical trial, testing a pill designed to enhance the body's ability to clear protein aggregates in Alzheimer's disease patients.